Mexiletine

Mexiletine
Clinical data
Trade names	Mexitil, NaMuscla
AHFS/Drugs.com	Monograph
MedlinePlus	a607064
License data	US DailyMed: Mexiletine;
Pregnancy; category	AU: B1; ;
Routes of; administration	By mouth, intravenous
ATC code	C01BB02 (WHO) ;
Legal status
Legal status	CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	90%
Protein binding	50–60%
Metabolism	Liver (CYP2D6 and 1A2-mediated)
Elimination half-life	10–12 hours
Excretion	Kidney (10%)
Identifiers
	IUPAC name (RS)-1-(2,6-dimethylphenoxy)propan-2-amine; OR2-(2-aminopropoxy)-1,3-dimethylbenzene;
CAS Number	31828-71-4 ;
PubChem CID	4178;
IUPHAR/BPS	2629;
DrugBank	DB00379 ;
ChemSpider	4034 ;
UNII	1U511HHV4Z;
KEGG	D08215 ; as HCl: D00639 ;
ChEBI	CHEBI:6916 ;
ChEMBL	ChEMBL558 ;
CompTox Dashboard (EPA)	DTXSID8048446 ;
ECHA InfoCard	100.046.190
Chemical and physical data
Formula	C11H17NO
Molar mass	179.263 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O(c1c(cccc1C)C)CC(N)C;
	InChI InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3 ; Key:VLPIATFUUWWMKC-UHFFFAOYSA-N ;
	(verify)

Mexiletine (INN) (sold under the brand names Mexitil and Namuscla) is a medication used to treat abnormal heart rhythms, chronic pain, and some causes of muscle stiffness. Common side effects include abdominal pain, chest discomfort, drowsiness, headache, and nausea. It works as a non-selective voltage-gated sodium channel blocker and belongs to the Class IB group of anti-arrhythmic medications.^[2]

^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
^ Canavero S, Bonicalzi V (13 October 2011). Central Pain Syndrome: Pathophysiology, Diagnosis and Management. Cambridge University Press. pp. 286–. ISBN 978-1-107-01021-5.

[1] "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.

[CanaveroBonicalzi2011-2] Canavero S, Bonicalzi V (13 October 2011). Central Pain Syndrome: Pathophysiology, Diagnosis and Management. Cambridge University Press. pp. 286–. ISBN 978-1-107-01021-5.

[1]

[2]